RxDoctor Payments Data

Joydev Acharya, MD

Cardiology · Modesto, CANPI 1801898044

Payments from drug & device makers

What this record shows

This record is dominated by other: $9,450 of the $12,270 with a category attached, or 77.0%. Angiodynamics, Inc. accounts for 77.0% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $7,209, more than ten times the $286 reported in 2019. Among cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,270in general payments, 2019–2025

Across 102 payments — averaging $120.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$9K
  • Abbott$2K
  • Medtronic$442
  • Biotronik Inc.$172
  • Johnson & Johnson$131
  • Shockwave Medical, Inc$97
  • plus $215 from 8 others

What the payments were for

  • Travel & lodging$5124%
  • Food & beverage$2,30819%
  • Other$9,45077%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,270 in reported general payments places this provider in the 90th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$370,790
Medicare patients
1,264
Services billed
4,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban636$534,585
XareltoRivaroxaban106$106,342
JardianceEmpagliflozin45$36,314
EntrestoSacubitril/Valsartan35$32,084
BrilintaTicagrelor59$28,458
Metoprolol Succinate380$4,706
Atorvastatin Calcium236$3,934
Diltiazem 24hr ErDiltiazem Hcl84$2,531
Flecainide Acetate100$2,361
ClopidogrelClopidogrel Bisulfate157$2,341
Ranolazine ErRanolazine28$2,101
Carvedilol170$1,840
Propafenone Hcl22$1,604
Amiodarone Hcl158$1,521
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide51$1,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$534,585636 claims
Johnson & JohnsonXarelto$131$106,342106 claims
NovartisEntresto$19$32,08435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 156 cardiology providers in California.

Other cardiology in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →